



## **Pixium Vision announces the drawdown of a further tranche, with a nominal value of €1.5 million, under the financing contract with ESGO**

**Paris, 19 April 2021** – 8.00 p.m. CET – Pixium Vision (FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces that it has issued a new tranche of 150 bonds with a nominal amount of €1,500,000, pursuant to the request of European Select Growth Opportunities Fund (“**ESGO**”), a US-based healthcare investor, to exercise 150 of the remaining 300 bond warrants.

This drawdown is in accordance with the provisions of the agreement with ESGO to provide financing for a maximum nominal amount of €10,000,000 over a period of 30 months, which was first announced on 6 November 2019<sup>1</sup>. In accordance with that agreement, on 18 February 2020<sup>2</sup>, the Company issued 875 bond warrants permitting the issue of a maximum of 875 bonds, with a maximum nominal borrowing amount of €8,750,000 if all bond warrants are exercised. Four tranches with a nominal value of €1,250,000 were issued in November 2019, February 2020, May 2020 and January 2021, respectively, and two tranches of €1,000,000 were issued in March 2021. After drawing down the new tranche of €1,500,000, there are 150 outstanding bond warrants that permit issuing a maximum of 150 bonds with a maximum nominal borrowing amount of €1,500,000 if all bond warrants are exercised<sup>3</sup>.

---

<sup>1</sup> Company press release dated 6 November 2019

<sup>2</sup> Company press release dated 19 February 2020

<sup>3</sup> In accordance with the agreements entered into, ESGO, at its sole discretion and subject to the fulfilment of certain conditions, had the option to subscribe for several tranches of bonds that, after the drawdown of this tranche, represent a maximum remaining amount of €500,000 (see press releases of 6 November 2019 and 12 June 2020).

## Contacts

### Pixium Vision

Lloyd Diamond  
Chief Executive Officer  
[investors@pixium-vision.com](mailto:investors@pixium-vision.com)  
+33 1 76 21 47 49

### Media Relations

**LifeSci Advisors**  
Sophie Baumont  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)  
+33 6 27 74 74 49

### Investor Relations

**LifeSci Advisors**  
Guillaume van Renterghem  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)  
+33 6 69 99 37 83

## ABOUT PIXIUM VISION

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](https://twitter.com/PixiumVision); [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

[Linkedin www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Growth Paris.  
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index

## Disclaimer

*This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, financial conditions, performance or achievements of Pixium Vision to be materially different from the results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Pixium Vision issues this press release as at this date and does not undertake to update any forward-looking statements contained herein, whether in response to new information, future events or otherwise. For a description of the risks and uncertainties that could cause the actual results, financial conditions, performance or achievements of Pixium Vision to differ from those contained in the forward-looking statements, please refer to section 3 "Risk Factors" of the Company's reference document, which was filed with the Autorité des Marchés Financiers under number D.20-0350 on 24 April 2020, and which can be viewed on the websites of the Autorité des marchés financiers - "AMF" ([www.amf-france.org](http://www.amf-france.org)) and Pixium Vision ([www.pixium-vision.com](http://www.pixium-vision.com)).*